(Q38193716)

30 August 2017

1 reference

title

What is the role of chemotherapy in the treatment of melanoma? (English)

1 reference

30 August 2017

1 reference

Ahmed I Megahed

1

1 reference

30 August 2017

Henry B Koon

series ordinal

2

1 reference

30 August 2017

language of work or name

1 reference

1 June 2014

1 reference

Current Treatment Options in Oncology

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

321-335

1 reference

Final version of 2009 AJCC melanoma staging and classification

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Phase II study of paclitaxel and carboplatin for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Phase II study of extended-dose temozolomide in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Impact of 3 Different Short-term Chemotherapy Regimens on Lymphocyte-depletion and Reconstitution in Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0277-5

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

21 January 2018

1 reference

12 December 2020

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

1 reference

12 December 2020

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

12 December 2020

Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide

1 reference

12 December 2020

Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.

1 reference

12 December 2020

Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway.

1 reference

12 December 2020

Phase I Study of Low-Dose Cyclophosphamide and Recombinant Interleukin-2 for the Treatment of Advanced Cancer

1 reference

12 December 2020

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

1 reference

12 December 2020

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma

1 reference

12 December 2020

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells

1 reference

12 December 2020

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.

1 reference

12 December 2020

Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma.

1 reference

12 December 2020

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

1 reference

12 December 2020

A phase II study of taxol in patients with malignant melanoma

1 reference

12 December 2020

Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)

1 reference

12 December 2020

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

12 December 2020

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma

1 reference

12 December 2020

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

1 reference

12 December 2020

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with advanced melanoma

1 reference

12 December 2020

10.1007/S11864-014-0277-5

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1024591558

0 references

1 reference